Département de Radiologie Interventionnelle, Gustave Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, 94805 Villejuif, France; Laboratoire de vectorologie et thérapeutiques anticancéreuses, UMR8203, Université Paris-Saclay, 94805 Villejuif, France.
Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.
Acta Biomater. 2019 Mar 15;87:177-186. doi: 10.1016/j.actbio.2019.01.054. Epub 2019 Jan 30.
Water-in-oil (W/O) Lipiodol emulsions remain the preferable choice for local delivery of chemotherapy in the treatment of hepatocellular carcinoma. However, their low stability severely hampers their efficiency. Here, remarkably stable W/O Lipiodol emulsion stabilized by biodegradable particles was developed thanks to Pickering technology. The addition of poly(lactide-co-glycolide) nanoparticles (NPs) into the aqueous-phase of the formulation led to W/O Pickering emulsion by a simple emulsification process through two connected syringes. Influence of nanoparticles concentration and water/oil ratio on emulsion stability and droplet size were studied. All formulated Pickering emulsions were W/O type, stable for at least one month and water droplets size could be tuned by controlling nanoparticle concentration from 24 µm at 25 mg/mL to 69 µm at 5 mg/mL. The potential of these emulsions to efficiently encapsulate chemotherapy was studied through the internalization of doxorubicin (DOX) into the aqueous phase with a water/oil ratio of 1/3 as recommended by the medical community. Loaded-doxorubicin was released from conventional emulsion within a few hours whereas doxorubicin from stable Pickering emulsion took up to 10 days to be completely released. In addition, in vitro cell viability evaluations performed on the components of the emulsion and the Pickering emulsion have shown no significant toxicity up to relatively high concentrations of NPs (3 mg/mL) on two different cell lines: HUVEC and HepG2. STATEMENT OF SIGNIFICANCE: We present an original experimental research in the field of nanotechnology for biomedical applications. In particular, we have formulated, thanks to Pickering technology, a new therapeutic emulsion stabilized with biodegradable PLGA nanoparticles. As far as we know, this is the first therapeutic Pickering emulsion reported in the literature for hepatocellular carcinoma. Such a new emulsion allows to easily prepare a predictable and stable lipiodolized emulsion having all the required characteristics for optimum tumor uptake. As demonstrated throughout our manuscript, emulsions stabilized with these nanoparticles have the advantage of being biodegradable, biocompatible and less toxic compared to usual emulsions stabilized with synthetic surfactants. These findings demonstrate the plausibility of the use of Pickering emulsions for chemoembolization as a therapeutic agent in extended release formulations.
水包油 (W/O) 型 Lipiodol 乳剂仍然是治疗肝细胞癌时局部递送化疗药物的首选。然而,其低稳定性严重限制了其效率。在此,得益于 Pickering 技术,开发了由可生物降解颗粒稳定的显著稳定的 W/O Lipiodol 乳剂。通过在制剂的水相中添加聚(乳酸-共-羟基乙酸)纳米颗粒 (NPs),通过两个连接的注射器通过简单的乳化过程形成 W/O Pickering 乳液。研究了纳米颗粒浓度和油水比对乳液稳定性和液滴尺寸的影响。所有配制的 Pickering 乳剂均为 W/O 型,至少稳定一个月,通过控制纳米颗粒浓度从 25mg/mL 时的 24μm 到 5mg/mL 时的 69μm 可调节水相尺寸。通过将水/油比为 1/3 时推荐的 doxorubicin (DOX) 包封到水相中,研究了这些乳剂高效包封化疗药物的潜力。负载 doxorubicin 的乳剂在数小时内从常规乳剂中释放,而稳定的 Pickering 乳剂中的 doxorubicin 则需要长达 10 天才能完全释放。此外,对乳剂成分和 Pickering 乳剂进行的体外细胞活力评估表明,在两种不同的细胞系:HUVEC 和 HepG2 上,即使 NPs 浓度高达 3mg/mL,也没有明显的毒性。 意义声明:我们在生物医学应用纳米技术领域提出了一项原创性的实验研究。特别是,我们借助 Pickering 技术,用可生物降解的 PLGA 纳米颗粒稳定地配制了一种新的治疗性乳剂。据我们所知,这是文献中首次报道用于肝细胞癌的治疗性 Pickering 乳剂。这种新的乳剂可以很容易地制备出具有最佳肿瘤摄取所需的所有特性的可预测和稳定的 Lipiodol 化乳剂。正如我们在整篇论文中所证明的,与通常用合成表面活性剂稳定的乳剂相比,用这些纳米颗粒稳定的乳剂具有生物降解性、生物相容性和低毒性的优点。这些发现证明了 Pickering 乳剂作为延长释放制剂中的治疗剂用于化学栓塞的可行性。